Back to top
more

Solventum Corporation (SOLV)

(Delayed Data from NYSE)

$72.43 USD

72.43
2,158,981

-2.64 (-3.52%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $72.30 -0.13 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (138 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up

by Zacks Equity Research

Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. The higher EPS outlook looks promising.

Solventum Q3 Earnings Likely to Reflect Declining Volume Trend

by Zacks Equity Research

SOLV's Q3 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset sales decline.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Veeva Systems Collaborates With Walgreens to Improve Patient Outcomes

by Zacks Equity Research

VEEV partners with Walgreens to provide better patient outcomes to life sciences companies.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

SOLV or MEDP: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SOLV vs. MEDP: Which Stock Is the Better Value Option?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Phibro Animal Health, Travelzoo, Ollie's Bargain Outlet in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

SOLV vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

SOLV vs. DOCS: Which Stock Is the Better Value Option?

Solventum Shares May Gain on the Launch of Its New V.A.C Therapy

by Zacks Equity Research

SOLV announces the launch of its V.A.C. Peel and Place Dressing for providing efficient and effective care in case of negative pressure wound therapy.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Philip Morris, IAMGOLD, Solventum in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised

by Zacks Equity Research

Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.